Fig. 2
From: The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
The tumor-killing mechanisms of blinatumomab and TrioMabs. Blinatumomab is an anti-CD3 × CD19 bispecific T-cell engager (BiTE) antibody. Blinatumomab is designed to bind to both CD19 of B cells and CD3 of T cells. By linking these two cell types, blinatumomab helps facilitate the T cell response against cancer cells, leading to the destruction of B-cell leukemia cells. Catumaxomab is an anti-CD3 × EpCAM BsAb based on TrioMabs technique, binding to EpCAM of cancer cells and CD3 of T cells. Notably, the Fc domain could bind to Fcγ receptor of effector cells including NK cells, macrophages, and dendritic cells, triggering antibody-dependent cell cytotoxicity or phagocytosis, and complement-dependent cytotoxicity against cancer cells (Adapted from “Bispecific Antibody Design”, by BioRender 2023)